

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### VOLUNTARY ANNOUNCEMENT

#### **ASCENTAGE PHARMA TO PRESENT FOUR STUDIES, INCLUDING AN ORAL REPORT FEATURING THE LATEST DATA OF OLVEREMBATINIB IN SDH-DEFICIENT GIST**

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) is pleased to announce that results from four clinical studies of the Company’s three key drug candidates have been selected for presentations, including an oral report, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The three key drug candidates are olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a Bcl-2-selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor.

The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. This year’s ASCO Annual Meeting will take place both online and in-person at the McCormick Place, Chicago, Illinois, the United States, from May 31, 2024 to June 4, 2024 (US local time).

These four clinical studies to be presented by Ascentage Pharma at this year’s ASCO Annual Meeting are as follows:

#### **Olverembatinib**

**Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma**

Abstract number: 11502

Format: Oral Report

Session Title: Sarcoma

First Author: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Date and Time: June 3, 2024, Monday, 3:24 PM – 3:36 PM (Central Time)/June 4, 2024, Tuesday, 4:24 AM – 4:36 AM (Beijing Time)

**APG-2575**

**Lisaftoclax**

**Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia**

Abstract number: 6541

Format: Poster Presentation

Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

First Author: Huafeng Wang, MD, PhD, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Date and Time: June 3, 2024, Monday, 9:00 AM – 12:00 PM (Central Time)/June 3, 2024, Monday 10:00 PM – June 4, 2024, Tuesday, 1:00 AM (Beijing Time)

**Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstrom macroglobulinemia**

Abstract number: 7078

Format: Poster Presentation

Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia

First Author: Masa Lasica, MBBS, FRACP, FRCPA, St Vincent's Hospital, Melbourne, Victoria, Australia.

Date and Time: June 3, 2024, Monday, 9:00 AM – 12:00 PM (Central Time)/June 3, 2024, 10:00 PM – June 4, 2024, 1:00 AM (Beijing Time)

## **APG-2449**

### **Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors**

Abstract number: 3124

Format: Poster Presentation

Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

First Author: Yuxiang Ma, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Date and Time: June 1, 2024, Saturday, 9:00 AM – 12:00 PM (Central Time)/June 1, 2024, Saturday, 10:00 PM – June 2, 2024, Sunday, 1:00 AM (Beijing Time)

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-2575 and APG-2449 successfully.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, April 25, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*